The Antimicrobial Products Subscription Model: consultation on proposals
Overview
Antimicrobial resistance (AMR) is one of the most pressing global challenges we face this century. Already, AMR infections are estimated to cause 700,000 deaths each year globally. That figure is predicted to rise to 10 million by 2050 if no action is taken. The World Bank estimates that, across the globe, an extra 28 million people will be forced into extreme poverty by 2050 unless AMR is contained.
The UK Government has recognised AMR as a global problem and committed international action to tackle it as a priority issue, focussed on antibiotic stewardship and infection prevention and control. The scale of the AMR threat, and the need to contain and control it, is widely acknowledged by governments globally, international agencies, researchers and private companies alike.
In July 2019, NHS England and NICE launched a pilot project, which was the first in the world to pay companies a fixed annual fee for antimicrobials based primarily on a health technology assessment of their value to the NHS, as opposed to the volumes used. This pilot project followed the UK Government’s national action plan for AMR which included the commitment to lead the way in testing solutions that address this market failure of companies not investing in the development of new antimicrobials.
Following the success of the pilot, the NHS is consulting on proposals for a subscription style contract that we will use to expand this approach to more antimicrobial products. The consultation will run from 10th July 2023 to the 2nd October 2023. We would like to hear from anyone with an interest in the proposals. People can respond by completing this online version or the questions found in annex A of the consultation document.
Supporting documentation
Audiences
- All interested stakeholders
Interests
- Any Interest
Share
Share on Twitter Share on Facebook